Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs Gemini Space Station Inc (GEMI) Price & Performance

Boston Scientific CorporationTrade
Gemini Space Station IncTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs Gemini Space Station Inc — how do they compare? Boston Scientific Corporation trades at $42.51 (market cap $66.37B), while Gemini Space Station Inc trades at $4.39 (market cap $548.72M). The key difference: Boston Scientific Corporation is far larger — about 121× Gemini Space Station Inc's market cap. Which is the better fit depends on your goals.

BSXGEMI
Market Cap
$66.37B$548.72M
Sector
HealthTechnology
52-Week High
$108.14$32.52
52-Week Low
$42.63$3.91
Enterprise Value
$75.94B$538.70M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.

BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.

Gemini Space Station Inc

GEMI trades at $4.25, down 1.39% on the day, amid a bearish technical signal and weak fundamentals. The company reported significant losses, with a net income margin of -278.9% in 2025, and has missed earnings expectations for three consecutive quarters. Recent news includes a class action lawsuit and a $100 million investment from Winklevoss Capital, creating mixed sentiment.

The outlook remains challenging due to persistent unprofitability and legal risks, though analyst consensus suggests moderate upside with a $5.88 price target. Investment opportunity hinges on the company's ability to leverage new capital for growth, but high execution and regulatory risks warrant caution.

Returns comparison

Trailing returns across standard periods

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About Gemini Space Station Inc

Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.

Read more on GEMI